Law360, New York (May 10, 2010, 7:17 PM ET) -- A federal appeals court has upheld Immutopics Inc.'s summary judgment of noninfringement victory in a Scantibodies Laboratory Inc. suit accusing the bone health assay manufacturer of infringing a patent for methods and devices to detect levels of parathyroid hormone in biological samples.
A three-judge panel in the U.S. Court of Appeals for the Federal Circuit on Thursday rejected Scantibodies' argument that the district court erred in construing a claim of the asserted patent, ruling that the plain meaning of the disputed claim “is fully consistent with...
Immutopics Didn't Infringe Antibody Patent: Fed. Circ.
To view the full article, take a free trial now.
